{"denomUnitsSelected":"Participants","description":"Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score \\[CPS\\]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 status. The association between PD-L1 CPS status and MMR IHC status will be assessed with odds ratios. A test may be conducted with a Fisher's Exact Test, and confidence intervals will be provided.","reportingStatus":"NOT_POSTED","timeFrame":"5 years","title":"Effect of Pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC","type":"OTHER_PRE_SPECIFIED"}